AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02281812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
Study NCT01021943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
Study NCT01021943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the subjects will be assigned to receive placebo for 6 months
Study NCT00860470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron (27 mg) - folic acid (600 ug)
Description: Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.
Study NCT00860470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient
Description: Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.
Study NCT01549990 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: maintenance of general anesthesia with sevoflurane
Study NCT01549990 — intervention group
Intervention type: DRUG
Intervention: desflurane
Description: maintenance of general anesthesia with desflurane
Study NCT03058484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker intervention
Description: The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
Study NCT03935971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: See arm/group description
Study NCT03268798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral wrist extension training
Description: Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
Study NCT00650923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT00650923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo RT
Study NCT00650923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT00650923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03653676 — intervention group
Intervention type: OTHER
Intervention: Exercise Test (CIIT)
Description: The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
Study NCT04023422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
Study NCT01218867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
Study NCT03894176 — intervention group
Intervention type: OTHER
Intervention: Plasma PTX3 concentration
Description: Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
Study NCT02879149 — intervention group
Intervention type: DEVICE
Intervention: AUGMENT® Bone Graft
Description: AUGMENT® Bone Graft
Study NCT02879149 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of Care
Description: Autologous Bone Graft
Study NCT04531631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dorzagliatin
Description: tablet
Study NCT03661918 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WiFi-enabled Scale
Description: Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
Study NCT04531631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo
Study NCT01218867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Study NCT03638843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal devitalization
Description: Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
Study NCT02694718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
Study NCT02694718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
Study NCT03705273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV for PO
Description: Common pediatric emergency department practice
Study NCT03705273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone crushed tablets
Description: Alternative route of administration for patients unable to swallow tablet whole
Study NCT03794882 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: 30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.
Study NCT03794882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Medical Management
Description: Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
Study NCT03794882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Management
Description: Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
Study NCT01218867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
Study NCT04023422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
Study NCT04023422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Description: The community health navigator will give the clinician real-time feedback on guideline-related health.
Study NCT04023422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The community health navigator will give the clinician real-time feedback on guideline-related health.
Study NCT03661918 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 10 Core Coaching Calls Only
Description: Participant will receive 10 core phone coaching sessions
Study NCT01949272 — intervention group
Intervention type: DEVICE
Intervention: esophageal pressure mesurement
Description: EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement
Study NCT00775034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisseel®
Description: Mesh repair for open incisional hernia repair with fibrin sealant
Study NCT00775034 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Drainage
Description: Mesh repair for open incisional hernia repair with drainage
Study NCT02082951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by nurses.
Description: The empathic behaviour in group 1 was performed by a trained nurse.
Study NCT01792362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Control the patients diet to make them loosing weight
Study NCT04415697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression test using nanostring technology.
Description: Evaluation of gene expression profile of a panel with 770 genes related to disease progression using nanostring technology
Study NCT01556763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.3 mg/day)
Description: EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
Study NCT02082951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by family.
Description: Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
Study NCT00494312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
Study NCT00494312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2
Description: Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3
Description: Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A5
Description: Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1
Description: Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2
Description: Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B3
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study NCT04261166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B4
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study NCT01556763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (1.0 mg/day)
Description: EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
Study NCT04596423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal echocardiography
Description: fetal heart examination by medical ultrasound
Study NCT01556763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo was administered as one capsule per day for 21 days.
Study NCT01556763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Study NCT01556763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotic therapy
Description: Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
Study NCT03003546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03003546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160
Description: Given IV
Study NCT03003546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03381508 — intervention group
Intervention type: DEVICE
Intervention: Brizzy continuous positive pressure device
Description: Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
Study NCT02353832 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
Description: Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
Study NCT02245100 — intervention group
Intervention type: OTHER
Intervention: Cytology specimen
Description: Correlative studies
Study NCT02245100 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study NCT06100380 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Questionnaire
Study NCT02126787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Group Analytic Psychotherapy
Description: The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes \& Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
Study NCT02126787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive transdiagnostic cognitive-behavioral group therapy
Description: GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, \& Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, \& Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
Study NCT05093751 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: This study does not involve any intervention to subjects.
Study NCT01706224 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine the presence of anti-pertussis antibodies.
Study NCT01706224 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Electronic Case Report Forms (eCRF)
Study NCT04681378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double layer step up-step down technique
Description: the incision is closed using Vicryl 1-0 stitch starting from one corner. The first layer is transversely passed through the inner myometrium-decidua line, and second layer is transversely passed through outer myometrium-visceral line continuously by alternating continuous stitches through the upper (step up) and the lower (step down) uterine flaps. The original string is returned to the starting point and tied with knot as in Turan technique. Following the double layered step up-step down closure, additional single sutures were added for hemostasis if required
Study NCT02090257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRANSIT
Description: Educational Modules, staff follow up.
Study NCT01432327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear display
Description: Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals.
Study NCT01432327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
Study NCT01432327 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SenseWear Armband
Description: Participants wear the SenseWear Armband for 4 weeks
Study NCT01432327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Coaching
Description: A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
Study NCT01706224 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaires, active questioning.
Study NCT02556450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolacton
Description: Administration of Spironolacton 25 mg per day
Study NCT01378520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 600 mg capsule oral once
Study NCT01378520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inert powder
Description: oral once
Study NCT04447820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER (Dose A)
Description: Dose A Oral Administration
Study NCT04447820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER (Dose B)
Description: Dose B Oral Administration
Study NCT04447820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-IR
Description: K-877-IR Oral Administration
Study NCT01890577 — intervention group
Intervention type: DRUG
Intervention: Aranesp
Description: Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
Study NCT03978390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral priming
Description: Priming the children with images of superheroes in order to behave desirably during the dental injection
Study NCT03978390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: endowment effect
Description: Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
Study NCT03978390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive reinforcement
Description: Giving rewards to the children at the end if they cooperate desirably during the treatment
Study NCT03978390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Description: Giving rewards to the children at the end if they cooperate desirably during the treatment
Study NCT00547105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.